NS309

Research use only, not for human use.

NS309 is a nonselective activator of small- and intermediate-conductance Ca2+-activated K+ (SK/KCa2 and IK/KCa3.1) channels (EC50s range from 0.12-1.2 μM for SK channels and 10-90 nM for IK channels).

NS309 is a nonselective activator of small- and intermediate-conductance Ca2+-activated K+ (SK/KCa2 and IK/KCa3.1) channels (EC50s range from 0.12-1.2 μM for SK channels and 10-90 nM for IK channels). It can also activate voltage-gated Kv11.1 channels (hERG; IC50 = 1 μM), but does not, however, affect large conductance (BK/KCa1.1) channels. NS309 can modulate neuronal firing patterns by enhancing SK-mediated hyperpolarizing effects. It is 730-fold (SK channels) and 7,400-fold (IK channels) more potent than 1-EBIO and often used in conjunction with CyPPA to distinguish between SK1 and SK3 subtypes.

NS309 (40?nM) activates both hSK3 and hIK channels, with the largest effect on hIK channels (8.5-fold increase in current compares to 1.9-fold increase in current for hSK3 channels).NS309 (10 μM) significantly increases the whole cell SK currents and hyperpolarized detrusor smooth muscle (DSM) cells resting membrane potential.NS309 inhibits the spontaneous phasic contraction amplitude, force, frequency, duration and tone of isolated DSM strips in a concentration-dependent manner.

NS309 (2 mg/kg; i.p.) protects against SCI/R in rabbits. Animal Model:Adult New Zealand white rabbits (2.5-3.0 kg)Dosage:2 mg/kg Administration:Intraperitoneal injection Result:Significantly improved neurological outcome of SCI/R challenged rabbits.

NS309 | NS-309 | NS 309

Immunology/Inflammation

ROS

Potassium Channel

Cardiovascular Disease

——

18711-16-5

231.04

C8H4Cl2N2O2

>98% (HPLC)

DMSO : ≥ 50 mg/mL; 216.41 mM

Clc2ccc1c(NC(=O)C1=NO)c2Cl

(Z)-6,7-dichloro-3-(hydroxyimino)indolin-2-one

(-20℃)

With Ice Pack

≥ 2 years